IgG4-Related Disease and Other Causes of Inflammatory Meningeal Disease

Robert Carruthers; Mollie Carruthers; Emanuel Della-Torre

doi:10.1055/s-0034-1390388

Seminars in Neurology, Table of Contents

Semin Neurol 2014; 34(04): 395-404
DOI: 10.1055/s-0034-1390388

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

IgG4-Related Disease and Other Causes of Inflammatory Meningeal Disease

Authors

Robert Carruthers

¹Department of Neurology, Brigham and Women's Hospital, Brookline, Massachusetts
Mollie Carruthers

²Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
Emanuel Della-Torre

³Department of Medicine and Clinical Immunology, IRCCS-San Raffaele Scientific Institute, Milan, Italy

Abstract

Immunoglobulin-4 (IgG4-) related disease is a newly described treatable condition that has recently expanded the differential diagnosis of inflammatory meningeal disorders. This review will discuss the main clinical and pathophysiological features of IgG4-related meningeal disease in the context of meningeal inflammatory disorders in general. Particular attention will be dedicated to the differential diagnosis and the different therapeutic approaches.

Keywords

pachymeningitis - IgG4-related disease - inflammatory meningeal disease

Full Text

References

References
1 Wallace ZS, Carruthers MN, Khosroshahi A , et al. IgG4-related disease and hypertrophic pachymeningitis. Medicine (Baltimore) 2013; 92 (4) 206-216
2 Lindstrom KM, Cousar JB, Lopes MB. IgG4-related meningeal disease: clinico-pathological features and proposal for diagnostic criteria. Acta Neuropathol 2010; 120 (6) 765-776
3 Shapiro KA, Bové RM, Volpicelli ER, Mallery RM, Stone JH. Relapsing course of immunoglobulin G4-related pachymeningitis. Neurology 2012; 79 (6) 604-606
4 Kim EH, Kim SH, Cho JM, Ahn JY, Chang JH. Immunoglobulin G4-related hypertrophic pachymeningitis involving cerebral parenchyma. J Neurosurg 2011; 115 (6) 1242-1247
5 Kosakai A, Ito D, Yamada S, Ideta S, Ota Y, Suzuki N. A case of definite IgG4-related pachymeningitis. Neurology 2010; 75 (15) 1390-1392
6 Regev K, Nussbaum T, Cagnano E, Giladi N, Karni A. Central nervous system manifestation of IgG4-related disease. JAMA Neurol 2014; 71 (6) 767-770
7 Shimatsu A, Oki Y, Fujisawa I, Sano T. Pituitary and stalk lesions (infundibulo-hypophysitis) associated with immunoglobulin G4-related systemic disease: an emerging clinical entity. Endocr J 2009; 56 (9) 1033-1041
8 Choi SH, Lee SH, Khang SK, Jeon SR. IgG4-related sclerosing pachymeningitis causing spinal cord compression. Neurology 2010; 75 (15) 1388-1390
9 Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366 (6) 539-551
10 Comings DE, Skubi KB, Van Eyes J, Motulsky AG. Familial multifocal fibrosclerosis. Findings suggesting that retroperitoneal fibrosis, mediastinal fibrosis, sclerosing cholangitis, Riedel's thyroiditis, and pseudotumor of the orbit may be different manifestations of a single disease. Ann Intern Med 1967; 66 (5) 884-892
11 Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med 2006; 4: 23
12 Hamano H, Kawa S, Horiuchi A , et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344 (10) 732-738
13 Kamisawa T, Funata N, Hayashi Y , et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38 (10) 982-984
14 Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2014;
15 Khosroshahi A, Cheryk LA, Carruthers MN, Edwards JA, Bloch DB, Stone JH. Brief report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheum (Munch) 2014; 66 (1) 213-217
16 Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010; 34 (12) 1812-1819
17 Hart PA, Topazian MD, Witzig TE , et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62 (11) 1607-1615
18 Deshpande V, Zen Y, Chan JK , et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25 (9) 1181-1192
19 Della Torre E, Bozzolo EP, Passerini G, Doglioni C, Sabbadini MG. IgG4-related pachymeningitis: evidence of intrathecal IgG4 on cerebrospinal fluid analysis. Ann Intern Med 2012; 156 (5) 401-403
20 Della-Torre E, Passerini G, Furlan R , et al. Cerebrospinal fluid analysis in immunoglobulin G4-related hypertrophic pachymeningitis. J Rheumatol 2013; 40 (11) 1927-1929
21 Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23 (1) 119-124
22 Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39 (4) 469-477
23 Mattoo H, Della-Torre E, Mahajan VS, Stone JH, Pillai S. Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. Allergy 2014; 69 (3) 399-402
24 Della Torre E, Mattoo H, Mahajan VS, Carruthers M, Pillai S, Stone JH. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy 2014; 69 (2) 269-272
25 Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160 (7) 3555-3561
26 Satoguina JS, Weyand E, Larbi J, Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol 2005; 174 (8) 4718-4726
27 Della-Torre E, Galli L, Franciotta D , et al. Diagnostic value of IgG4 Indices in IgG4-related hypertrophic pachymeningitis. J Neuroimmunol 2014; 266 (1-2) 82-86
28 Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184 (2) 101-122
29 Tomiyama T, Uchida K, Matsushita M , et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol 2011; 46 (5) 696-704
30 Ghazale A, Chari ST, Zhang L , et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134 (3) 706-715
31 Sandanayake NS, Church NI, Chapman MH , et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7 (10) 1089-1096
32 Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62 (6) 1755-1762
33 Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012; 91 (1) 57-66
34 Stone JH. Rituximab in IgG4-related Disease: A Phase 1-2 Trial. 2012. Available at: http://clinicaltrials.gov/show/NCT01584388 . Accessed October 1, 2014
35 Woywodt A, Matteson EL. Wegener's granulomatosis—probing the untold past of the man behind the eponym. Rheumatology (Oxford) 2006; 45 (10) 1303-1306
36 Di Comite G, Bozzolo EP, Praderio L, Tresoldi M, Sabbadini MG. Meningeal involvement in Wegener's granulomatosis is associated with localized disease. Clin Exp Rheumatol 2006; 24 (2) (Suppl. 41) S60-S64
37 Yokoseki A, Saji E, Arakawa M , et al. Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 2014; 137 (Pt 2) 520-536
38 Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42 (9) 909-917
39 Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102 (7) 449-460
40 Langrand C, Bihan H, Raverot G , et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM 2012; 105 (10) 981-995
41 Ranoux D, Devaux B, Lamy C, Mear JY, Roux FX, Mas JL. Meningeal sarcoidosis, pseudo-meningioma, and pachymeningitis of the convexity. J Neurol Neurosurg Psychiatry 1992; 55 (4) 300-303
42 Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J , et al. Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol 2014; 32 (2) 275-284
43 Starosta MA, Brandwein SR. Clinical manifestations and treatment of rheumatoid pachymeningitis. Neurology 2007; 68 (13) 1079-1080
44 Jones SE, Belsley NA, McLoud TC, Mullins ME. Rheumatoid meningitis: radiologic and pathologic correlation. AJR Am J Roentgenol 2006; 186 (4) 1181-1183
45 Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum 1989; 18 (4) 258-266
46 Ii Y, Kuzuhara S. Rheumatoid cranial pachymeningitis successfully treated with long-term corticosteroid. Rheumatol Int 2009; 29 (5) 583-585
47 Kato T, Hoshi K, Sekijima Y , et al. Rheumatoid meningitis: an autopsy report and review of the literature. Clin Rheumatol 2003; 22 (6) 475-480
48 Markenson JA, McDougal JS, Tsairis P, Lockshin MD, Christian CL. Rheumatoid meningitis: a localized immune process. Ann Intern Med 1979; 90 (5) 786-789
49 Xia Z, Chen-Plotkin A, Schmahmann JD. Hypertrophic pachymeningitis and cerebral venous sinus thrombosis in inflammatory bowel disease. J Clin Neurosci 2010; 17 (11) 1454-1456
50 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335 (8697) 1078-1080
51 Kalra S, Silman A, Akman-Demir G , et al. Diagnosis and management of neuro-Behçet's disease: international consensus recommendations. J Neurol 2013;
52 Akman-Demir G, Serdaroglu P, Tasçi B. The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999; 122 (Pt 11) 2171-2182
53 Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain 1999; 122 (Pt 11) 2183-2194
54 Pipitone N, Olivieri I, Padula A , et al. Infliximab for the treatment of neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008; 59 (2) 285-290
55 Goldgeier MH, Klein LE, Klein-Angerer S, Moellmann G, Nordlund JJ. The distribution of melanocytes in the leptomeninges of the human brain. J Invest Dermatol 1984; 82 (3) 235-238
56 Kamondi A, Szegedi A, Papp A, Seres A, Szirmai I. Vogt-Koyanagi-Harada disease presenting initially as aseptic meningoencephalitis. Eur J Neurol 2000; 7 (6) 719-722
57 Nakamura S, Nakazawa M, Yoshioka M , et al. Melanin-laden macrophages in cerebrospinal fluid in Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol 1996; 114 (10) 1184-1188
58 Greco A, Fusconi M, Gallo A , et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 2013; 12 (11) 1033-1038
59 Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol (Copenh) 2012; 90 (8) e603-e608
60 Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol 1972; 3 (4) 457-558
61 Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 1997; 30: 233-248
62 Patsalides AD, Atac G, Hedge U , et al. Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology 2005; 237 (1) 265-273
63 Wilson WH, Grossbard ML, Pittaluga S , et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99 (8) 2685-2693
64 Chan SK, Cheuk W, Chan KT, Chan JK. IgG4-related sclerosing pachymeningitis: a previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am J Surg Pathol 2009; 33 (8) 1249-1252
65 Kato K, Tamano Y, Namioka A , et al. [Hypertrophic pachymeningitis associated with autoimmune pancreatitis examined for IgG4 related disease: a case report]. No Shinkei Geka 2011; 39 (8) 763-768
66 Moss HE, Mejico LJ, de la Roza G, Coyne TM, Galetta SL, Liu GT. IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil. J Neurol Sci 2012; 318 (1-2) 31-35
67 Norikane T, Yamamoto Y, Okada M , et al. Hypertrophic cranial pachymeningitis with IgG4-positive plasma cells detected by C-11 methionine PET. Clin Nucl Med 2012; 37 (1) 108-109
68 Tajima Y, Mito Y. Cranial neuropathy because of IgG4-related pachymeningitis; intracranial and spinal mass lesions. BMJ Case Rep 2012; doi:10.1136/bcr-2012-006471
69 Yamashita H, Takahashi Y, Ishiura H, Kano T, Kaneko H, Mimori A. Hypertrophic pachymeningitis and tracheobronchial stenosis in IgG4-related disease: case presentation and literature review. Intern Med 2012; 51 (8) 935-941
70 Lin CK, Lai DM. IgG4-related intracranial hypertrophic pachymeningitis with skull hyperostosis: a case report. BMC Surg 2013; 13: 37
71 Imbergamo S, Campagnolo M, Manara R, Marino F, Adami F, Briani C. Teaching NeuroImages: multifocal neurologic involvement as the only manifestation of IgG4-related disease. Neurology 2013; 80 (4) e40-e41
72 Utsuki S, Kijima C, Fujii K, Miyakawa S, Iizuka T, Hara A. Investigation of IgG4-positive cell infiltration in biopsy specimens from cases of hypertrophic pachymeningitis. Clin Neuropathol 2013; 32 (2) 84-90
73 Lipton S, Warren G, Pollock J, Schwab P. IgG4-related disease manifesting as pachymeningitis and aortitis. J Rheumatol 2013; 40 (7) 1236-1238
74 Makino S, Tanaka Y. A case of hypertrophic pachymeningitis with elevated serum IgG4. J Clin Exp Opthalmol 2013; 4: 260
75 Tanboon J, Felicella MM, Bilbao J, Mainprize T, Perry A. Probable IgG4-related pachymeningitis: a case with transverse sinus obliteration. Clin Neuropathol 2013; 32 (4) 291-297
76 Hyun JW, Kim SH, Yoo H, Hong EK, Huh SY, Kim HJ. Steroid-resistant relapsing IgG4-related pachymeningitis treated with methotrexate. JAMA Neurol 2014; 71 (2) 222-225
77 Mehta SH, Switzer JA, Biddinger P, Rojiani AM. IgG4-related leptomeningitis: a reversible cause of rapidly progressive cognitive decline. Neurology 2014; 82 (6) 540-542